ProMetic Life Sciences (OTCMKTS:PFSCF) and Alterity Therapeutics (NASDAQ:ATHE) Head to Head Comparison

Alterity Therapeutics (NASDAQ:ATHE) and ProMetic Life Sciences (OTCMKTS:PFSCF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Institutional and Insider Ownership

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alterity Therapeutics and ProMetic Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%

Valuation and Earnings

This table compares Alterity Therapeutics and ProMetic Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87 million	N/A	N/A
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A

Alterity Therapeutics has higher earnings, but lower revenue than ProMetic Life Sciences.

Analyst Recommendations

This is a summary of current ratings and price targets for Alterity Therapeutics and ProMetic Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1	1	4	0	2.50
ProMetic Life Sciences	0	0	0	0	0.00

Alterity Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 112.77%. Given Alterity Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than ProMetic Life Sciences.

Risk and Volatility

Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500.

Summary

Alterity Therapeutics beats ProMetic Life Sciences on 9 of the 11 factors compared between the two stocks.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.